The authors give a comprehensive catalogue of well reported lncRNAs in non-alcoholic fatty liver disease (NAFLD) and classify them using sequence and synteny-based evolutionary conservation across rodents, nonhuman primate and human species.
Inventiva announced that the FDA has granted Breakthrough Therapy designation to lanifibranor, the company’s lead drug candidate, for the treatment of NASH.
6445212 nan items 1 apa default asc 1
Investigators provide succinct insights into the molecular mechanisms responsible for lipotoxicity in non-alcoholic fatty liver disease (NAFLD), including ER and oxidative stress, autophagy, lipoapotosis and inflammation. They highlight the role of CD36/FAT fatty acid translocase in NAFLD pathogenesis.
[Cell Death & Disease]
Scientists observed that Steatohepatitis-associated circRNA ATP5B Regulator (SCAR), which is located in mitochondria, inhibited mitochondrial ROS output and fibroblast activation.
6630899 UNMH95W6 items 1 apa default asc 1
89bio, Inc. has announced positive topline results from its Phase Ib/IIa trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH).
Theratechnologies Inc. has announced that it plans to pursue Phase III clinical development of tesamorelin for the treatment of non-alcoholic steatohepatitis (NASH) in the general population.
[Theratechnologies Inc. (GloveNewswire Inc.)]
Diseases like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) bring a very high level of pathogenic complexity and far-reaching implications that apply not only scientists but also to clinicians, patients, regulators, bio-pharmaceutical industry and third-party payers.
[Journal of Hepatology]
6630899 NKJ6EE9T items 1 apa default asc 1
Madrigal Pharmaceuticals, Inc. announced that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments.
[Madrigal Pharmaceuticals, Inc. (GlobeNewswire)]
Engitix Ltd is developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform. They have entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company Ltd. to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
[Engitix Ltd. ]
Two years after nabbing three novel anti-infective drug candidates from Swiss pharma giant Novartis for the treatment of antibiotic-resistant infections, Boston Pharma struck another deal, this time for a potential treatment for Non-Alcoholic Steatohepatitis (NASH).
[Boston Pharmaceuticals (BioSpace)]
Scientists demonstrated that Kupffer cells (KCs) were reduced in metabolic-associated fatty liver disease, being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated macrophages from obese adipose tissue.
6630899 N2WXZIIX items 1 apa default asc 1
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., Prijck, S. D., Vanhockerhout, M., Latib, M. B. A., Devisscher, L., Hoorens, A., Bonnardel, J., Vandamme, N., Kremer, A., Borghgraef, P., Vlierberghe, H. V., Lippens, S., … Scott, C. L. (2020). Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2020.08.004 Cite